Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 6/2016

01-06-2016 | Original Article

Effects of pre-radiation exposure to LLLT of normal and malignant cells

Authors: Andrei Barasch, Judith Raber-Durlacher, Joel B. Epstein, James Carroll

Published in: Supportive Care in Cancer | Issue 6/2016

Login to get access

Abstract

Purpose

Low-level laser therapy (LLLT) efficacy for the prevention of cancer treatment-induced oral mucositis (OM) has been amply described. However, potential protection of malignant cells remains a legitimate concern for clinicians. We tested LLLT-induced protection from ionizing radiation killing in both malignant and normal cells.

Methods

We treated six groups each of normal human lymphoblasts (TK6) and human leukemia cells (HL60) with He-Ne LLLT (632.8 nm, 35 mW, CW, 1 cm2, 35 mW/cm2 for 3–343 s, 0.1–12 J/cm2) prior to exposure to ionizing radiation (IR). Cells were then incubated and counted daily to determine their survival. Optimization of IR dose and incubation time was established prior to testing the effect of LLLT.

Results

Growth curves for both cell lines showed significant declines after exposure to 50–200 cGy IR when compared to controls. Pre-radiation exposure to LLLT (4.0 J/cm2) followed by 1-h incubation blocked this decline in TK6 but not in HL60 cells. The latter cells were sensitized to the killing effects of IR in a dose-dependent manner.

Conclusion

This study shows that pre-IR LLLT treatment results in a differential response of normal vs. malignant cells, suggesting that LLLT does not confer protection and may even sensitize cancer cells to IR killing.
Literature
1.
Elting LS, Keefe DM, Sonis ST et al (2008) Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. Cancer 113:2704–2713CrossRefPubMed
2.
Barasch A, Coke JM (2007) Cancer therapeutics: an update on its effects on oral health. Periodontology 2000 44:44–54CrossRefPubMed
3.
Lalla RV, Bowen J, Barasch A et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 121:1453–1461CrossRef
4.
Clarkson JE, Worthington HV, Furness S et al (2010) Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. Issue 8. Art. No.: CD001973
5.
Bjordal JM, Bensadoun RJ, Tuner J et al (2011) A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis (OM). Support Care Cancer 19:1069–1077CrossRefPubMed
6.
Jenkins PA, Carroll JD (2011) How to report low-level laser therapy (LLLT)/photomedicine dose and beam parameters in clinical and laboratory studies. Photomed Laser Surg 29:785–787CrossRefPubMed
7.
Barasch A, Peterson DE, Tanzer JM et al (1995) Helium-Neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 76:2550–2556CrossRefPubMed
8.
Schartinger VH, Galvan O, Riechelmann H, Dudas J (2012) Differential responses of fibroblasts, non-neoplastic epithelial cells, and oral carcinoma cells to low-level laser therapy. Support Care Cancer 20:523–529CrossRefPubMed
9.
Sperandio FF, Giudice FS, Correa L et al (2013) Low-level laser therapy can produce increased aggressiveness of dysplastic and oral cancer cell lines by modulation of Akt/mTOR signaling pathway. J Biophotonics 6:839–847PubMedPubMedCentral
10.
Kreisler M, Christoffers AB, Willershausen B, D’Hoedt B (2003) Low level 809 nm GaAlAs laser irradiation increases the proliferation rate of human laryngeal carcinoma cells in vitro. Lasers Med Sci 18:100–103CrossRefPubMed
11.
Eells JT, Wong-Riley MT, Verhoeve J et al (2004) Mitochondrial signal transduction in accelerated wound and retinal healing by near-infrared light therapy. Mitochondrion 4:559–567CrossRefPubMed
12.
Chen AC, Arany PR, Huang YY et al (2011) Low-level laser therapy activates NF-kB via generation of reactive oxygen species in mouse embryonic fibroblasts. PLoS One 6:e22453CrossRefPubMedPubMedCentral
13.
Arany PR, Nayak RS, Hallikerimath S et al (2007) Activation of latent TGF-beta1 by low-power laser in vitro correlates with increased TGF-beta1 levels in laser-enhanced oral wound healing. Wound Repair Regen 15:866–874CrossRefPubMed
14.
Lopes NNF, Plapler H, Chavantes MC et al (2009) Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols. Support Care Cancer 17:1409–1415CrossRefPubMed
15.
Antunes HS, Herchenhorn D, Small IA et al (2013) Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation. Radiother Oncol 109:297–302CrossRefPubMed
Metadata
Title
Effects of pre-radiation exposure to LLLT of normal and malignant cells
Authors
Andrei Barasch
Judith Raber-Durlacher
Joel B. Epstein
James Carroll
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 6/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-3051-8

Other articles of this Issue 6/2016

Supportive Care in Cancer 6/2016 Go to the issue

Original Article

Evaluation of the treatment of chronic chemotherapy-induced peripheral neuropathy using long-wave diathermy and interferential currents: a randomized controlled trial

Original Article

Predictors of quality of life in head and neck cancer survivors up to 5 years after end of treatment: a cross-sectional survey

Original Article

Effectiveness of acupuncture in rehabilitation of physical and functional disorders of women undergoing breast cancer surgery

Original Article

Systematic review of reduced therapy regimens for children with low risk febrile neutropenia

Original Article

Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy—results from the prospective multi-center study BRENDA II

Original Article

Mixed method exploration of the medical, service-related, and emotional reasons for emergency room visits of older cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits